Loading
Loading
Research Overview
11-amino-acid peptide derived from the prohormone region of preprodopamine; proposed direct neurotrophic action on dopaminergic neurons in preclinical Parkinson's-model paradigms via mechanisms not fully characterised.
Overview
DNSP-11 is a short peptide sequence found in the prohormone region of the dopamine precursor preprodopamine. Preclinical research has investigated whether this naturally-derived sequence possesses neurotrophic or neuroprotective properties toward dopaminergic neurons — the neuronal population that degenerates in Parkinson's disease.
Animal model research has used dopaminergic neurotoxicity paradigms (such as 6-OHDA and MPTP models) to examine whether DNSP-11 administration affects dopaminergic neuron survival, dopamine turnover, and behavioural outcomes related to motor function. The proposed mechanism involves direct neurotrophic action on dopaminergic cell populations.
DNSP-11 is a highly experimental compound with no standardised human dosing protocol and no published human safety data. Its extremely short plasma half-life (minutes) and the use of intracranial routes in some animal studies present significant barriers to translational research.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, dnsp-11 has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
11-amino-acid peptide derived from the prohormone region of preprodopamine; proposed direct neurotrophic action on dopaminergic neurons in preclinical Parkinson's-model paradigms via mechanisms not fully characterised.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.